首页> 美国卫生研究院文献>Oncotarget >Rapid detection of copy number variations and point mutations in BRCA1/2 genes using a single workflow by ion semiconductor sequencing pipeline
【2h】

Rapid detection of copy number variations and point mutations in BRCA1/2 genes using a single workflow by ion semiconductor sequencing pipeline

机译:通过离子半导体测序管线使用单个工作流程快速检测BRCA1 / 2基因中的拷贝数变异和点突变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Molecular analysis of BRCA1 (MIM# 604370) and BRCA2 (MIM #600185) genes is essential for familial breast and ovarian cancer prevention and treatment. An efficient, rapid, cost-effective accurate strategy for the detection of pathogenic variants is crucial. Mutations detection of BRCA1/2 genes includes screening for single nucleotide variants (SNVs), small insertions or deletions (indels), and Copy Number Variations (CNVs). Sanger sequencing is unable to identify CNVs and therefore Multiplex Ligation Probe amplification (MLPA) or Multiplex Amplicon Quantification (MAQ) is used to complete the BRCA1/2 genes analysis. The rapid evolution of Next Generation Sequencing (NGS) technologies allows the search for point mutations and CNVs with a single platform and workflow. In this study we test the possibilities of NGS technology to simultaneously detect point mutations and CNVs in BRCA1/2 genes, using the OncomineTM BRCA Research Assay on Personal Genome Machine (PGM) Platform with Ion Reporter Software for sequencing data analysis (Thermo Fisher Scientific). Comparison between the NGS-CNVs, MLPA and MAQ results shows how the NGS approach is the most complete and fast method for the simultaneous detection of all BRCA mutations, avoiding the usual time consuming multistep approach in the routine diagnostic testing of hereditary breast and ovarian cancers.
机译:BRCA1(MIM#604370)和BRCA2(MIM#600185)基因的分子分析对于家族性乳腺癌和卵巢癌的预防和治疗至关重要。一个高效,快速,具有成本效益的准确策略,对于检测病原体变异至关重要。 BRCA1 / 2基因的突变检测包括筛选单核苷酸变体(SNV),小的插入或缺失(indels)和拷贝数变异(CNV)。 Sanger测序无法识别CNV,因此使用多重连接探针扩增(MLPA)或多重扩增定量(MAQ)来完成BRCA1 / 2基因分析。下一代测序(NGS)技术的快速发展,使得可以通过单一平台和工作流程搜索点突变和CNV。在这项研究中,我们使用Ion Reporter软件在个人基因组机(PGM)平台上使用Oncomine TM BRCA研究检测技术,通过NGS技术检测BRCA1 / 2基因中点突变和CNV的可能性,以用于测序数据分析(Thermo Fisher Scientific)。 NGS-CNV,MLPA和MAQ结果之间的比较表明,NGS方法是同时检测所有BRCA突变的最完整,最快速的方法,从而避免了遗传性乳腺癌和卵巢癌的常规诊断测试中通常耗时的多步骤方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号